Is CDKN2A p.Gly89Asp (c.266G>A) pathogenic?

CDKN2A p.Gly89Asp (c.266G>A) is classified Pathogenic/Likely pathogenic in CDKN2A (ClinVar, Multiple submitters, 8 submitters; last evaluated 2024-09-24). AlphaMissense: likely pathogenic (0.9296); Absent from gnomAD v4.1; Associated with hereditary neoplastic syndrome.

What condition is associated with CDKN2A p.Gly89Asp (c.266G>A)?

CDKN2A p.Gly89Asp (c.266G>A) is associated with hereditary neoplastic syndrome, melanoma, cutaneous malignant, susceptibility to, 2, melanoma-pancreatic cancer syndrome (ClinVar).

How common is CDKN2A p.Gly89Asp (c.266G>A) in the general population?

CDKN2A p.Gly89Asp (c.266G>A) is absent from gnomAD v4.1 (gnomAD).

What do computational predictors say about CDKN2A p.Gly89Asp (c.266G>A)?

AlphaMissense predicts likely pathogenic (score 0.9296) — an in-silico prediction, not a clinical call.

CDKN2A p.Gly89Asp

c.266G>A · rs137854599 · VCV9426

Pathogenic/Likely pathogenic Multiple submitters

Classification

Pathogenic/Likely pathogenic

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 8 submitters

AlphaMissense

likely pathogenic

0.9296 · ACMG-weighted

gnomAD v4.1

Not reported

no allele count reported in gnomAD v4.1 (AN 1,604,966)

Missense predictors

3/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

hereditary neoplastic syndrome

Computational evidence

Protein change
AlphaMissense	0.9296	likely pathogenic ✓ concordant with ClinVar · top 8% in CDKN2A
REVEL	0.74	pathogenic-leaning
SaProt	LLR -14.39	damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 7.5	GERP 2, phastCons 1
Regional constraint	o/e 1.13	unconstrained · MANE · 6,595 bp · p 0.04 · regional, not allelic
Overall
CADD	27.3	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

No allele count reported in gnomAD v4.1 (AN 1,604,966). This is missing data, not an absence: the variant may or may not be present in gnomAD. Rarity (ACMG PM2) and BA1/BS1 cannot be assessed for it.

Variant & gene context

Gene: CDKN2A
Protein: p.Gly89Asp
Coding: c.266G>A
MANE Select: NM_000077
dbSNP: rs137854599
Type: single nucleotide variant
Location: chr9:21971093 (GRCh38)
Gene constraint: LOEUF 0.791 · pLI 0.62 · ClinGen HI 3/3 (gnomAD)
Structure: AlphaFold pLDDT 77.02 · 5 PDB
Residue 89: a UniProt-annotated variant site (in cmm2; somatic mutation); a UniProt-annotated variant site (in cmm2); the 'disordered' region

Full CDKN2A gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

hereditary neoplastic syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: melanoma, cutaneous malignant, susceptibility to, 2 melanoma-pancreatic cancer syndrome familial melanoma

Similar variants

CDKN2A p.Gly89Ser Uncertain significance ★★ ⚠ same residue
CDKN2A p.Gly89= Conflicting classifications of pathogenicity ★ same residue
CDKN2A p.Gly89Ala Uncertain significance ★ ⚠ same residue
CDKN2A p.Gly89Cys Uncertain significance ★ ⚠ same residue
CDKN2A p.Gly89Val Uncertain significance ★ ⚠ same residue
CDKN2A c.150+1G>A Likely pathogenic ★★ same condition
CDKN2A c.150+2T>G Likely pathogenic ★★ same condition
CDKN2A c.151-1G>A Pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/cdkn2a-p-gly89asp (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown